1. Scrip
  2. >>Archive

Ark Therapeutics Ltd.

 
• By Melanie Senior

The founders of MediGene AG and Eurogene Ltd. have formed Ark Therapeutics to combat cardiovascular diseases such as de novo stenosis through the delivery of VEGF by gene therapy. The new company possesses the pieces that it hopes will allow it to go from identifying genes to producing medicines; functional genomics, gene vector and animal research capabilities, biology, chemistry, gene delivery development and clinical expertise.

Gene therapy is well suited to treating site-specific disorders, particularly those that require only short-term gene expression. Cardiovascular disease is ripe territory for gene therapy companies, therefore, since blood vessels are easy to access and in many conditions, such as vascular blockages following bypass graft surgery (stenosis), or following angioplasty (restenosis), benefits can be achieved even after transient gene expression.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

EU Approves Tremfya In Third Indication, Ulcerative Colitis

 
• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By Vibha Ravi

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs

In Brief: Amgen Invests $900m In US Manufacturing

 
• By Sushmita Panda

Amgen announces major expansion of existing US site amid ongoing threat of pharma import tariffs.